Upcoming earnings and continued AI cluster connectivity ramps.
Best fit for Edge Computing & Memory preference: 89% growth, EBITDA positive, reasonable 4.2x sales, and direct exposure to AI networking bottlenecks with durable hyperscaler demand.
2026年3月13日
KTOS
Defense award flow and autonomous systems program scaling.
Clean Defense & Hard Tech fit with real revenue, 21% growth, EBITDA positive operations, and backlog-backed modernization demand without extreme valuation.
2026年3月13日
CRSP
Commercialization progress and pipeline/regulatory updates.
Among Biotech 2.0 names it has meaningful commercial/partner revenue, strong growth, catalyst score above 70, low dilution risk, and >18 months runway.
2026年3月13日
ARQT
Prescription uptake and margin improvement into earnings.
Commercial-stage biotech with 64% growth, acceptable 5.3x sales, low modeled dilution risk, and a credible path toward breakeven rather than pure binary science.